MCL-1 INHIBITORS

The present disclosure generally relates to compounds of general Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of myeloid cell leukemia 1 protein (MCL-1 ), and pharmaceutical compositions thereof that may be used treating cancer. La présente divulgation concerne gé...

Full description

Saved in:
Bibliographic Details
Main Authors LIN, DAVID W, HURTLEY, ANNA E, YANG, HONG, NEWBY, ZACHARY, SQUIRES, NEIL H, KATO, DARRYL, LI, XIAOFEN, WATKINS, WILLIAM J, KOBAYASHI, TETSUYA, MITCHELL, MICHAEL L, KNOX, JOHN E, MEDLEY, JONATHAN W, VENKATARAMANI, CHANDRASEKAR, GUERRERO, JUAN A, JIANG, LAN, NADUTHAMBI, DEVAN, LAZERWITH, SCOTT E, HWANG, TAE H, TSUI, VICKIE H, CHU, HANG
Format Patent
LanguageEnglish
French
Published 21.11.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure generally relates to compounds of general Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of myeloid cell leukemia 1 protein (MCL-1 ), and pharmaceutical compositions thereof that may be used treating cancer. La présente divulgation concerne généralement des composés de formule générale (I) : et des sels acceptables sur le plan pharmaceutique, qui sont des inhibiteurs de la protéine de leucémie de cellule myéloïde 1 (MCL-1), et des compositions pharmaceutiques connexes utiles dans le traitement du cancer.
Bibliography:Application Number: CA20193099152